hi, thanks for leaving a comment. I do stick by greater than. For radical radiotherapy you would ideally want the FEV1 greater than 1L. Of course there are instances where you would give often give RT in poorer lung function, eg palliative/high dose palliative or SAbR (even with gross ILD under specialised services). But this generalised cut off is more for radical chemoRT/radical RT in locally advanced disease.
2019 NICE guidelines. Purely judicious use of resources. Risk of occult brain mets higher in Stage III, higher pre test probability and thus more sensitive test used to identify disease. Slightly lower pre test probability in Stage II but would like to rule out anything obvious.
The CDF if a publicly available document. I would recommend checking if anything has changed since the notes were written. These notes are intended to help you make your own notes and are not gospel! (as far as I am aware first line is still brigatinib or alectinib in the NHS, NCCN do include loratinib though)
The CLINICAL ONCOLOGY REGISTRAR 
FEV1 >1L Radiotherapy or >40% predicted & TLCO >50% predicted
I THINK IT SHOULD BE LESS THAN <
LikeLike
hi, thanks for leaving a comment. I do stick by greater than. For radical radiotherapy you would ideally want the FEV1 greater than 1L. Of course there are instances where you would give often give RT in poorer lung function, eg palliative/high dose palliative or SAbR (even with gross ILD under specialised services). But this generalised cut off is more for radical chemoRT/radical RT in locally advanced disease.
LikeLiked by 1 person
Hi
For brain imaging what is the rationale of doing CT head in stage 2 but MRI brain in stage 3?
LikeLike
2019 NICE guidelines. Purely judicious use of resources. Risk of occult brain mets higher in Stage III, higher pre test probability and thus more sensitive test used to identify disease. Slightly lower pre test probability in Stage II but would like to rule out anything obvious.
LikeLike
Hi
Indication for post op adjuvant chemo – N+ve ,T size > 4cm
but as T dint mention so people might get confused if possible could you edit it and put t size
LikeLike
Thanks.
LikeLike
Hi
So Lorlatinib is yet to be in first line setting in ALK mutated patients under CDF ?
LikeLike
The CDF if a publicly available document. I would recommend checking if anything has changed since the notes were written. These notes are intended to help you make your own notes and are not gospel! (as far as I am aware first line is still brigatinib or alectinib in the NHS, NCCN do include loratinib though)
LikeLike